Fig 1.

Plasma HCV RNA concentration and danoprevir susceptibility during monotherapy. (A) Median HCV RNA as a function of time in rebound, plateau, and continuous-decline groups. (B) Danoprevir susceptibility as a function of time in individual rebound, plateau, and continuous-decline patients as indicated. Potency determined in a cell-based assay by at least three independent experiments (12) against a pool of sequences representing the entire quasispecies population in the patient at that time. Median indicated by horizontal bar. Arrows emphasize single rebound patient with compromised danoprevir susceptibility at days 3 and 7. Daggers and double daggers indicate plateau and continuous-decline patients, respectively, with reduced danoprevir susceptibility at day 14 (EOT).